Inmode Ltd. Stock Price, News & Analysis

InMode Ltd. (NASDAQ: INMD) announced expectations for record revenue for Q3 2021, projecting between $93.5M and $94M. The company also anticipates Non-GAAP earnings per diluted share to be in the range of $0.53 to $0.54, reflecting a 2-for-1 stock split effective September 30, 2021. Full-year revenue guidance has been raised to $343M - $347M with a Non-GAAP gross margin of 84% - 86%. A conference call to discuss results will take place on October 26, 2021.

InMode Ltd. (Nasdaq: INMD) has announced a two-for-one (2:1) share split, effective September 30, 2021, with a record date of September 27, 2021. Every share held by shareholders on the record date will automatically convert into two shares, impacting all shareholders uniformly without affecting their ownership percentage. The share split was approved by the board of directors on September 14, 2021. This move aims to enhance the liquidity of the shares and make them more accessible to investors.

InMode Ltd. (Nasdaq: INMD), a leader in innovative medical technologies, will participate in two upcoming virtual conferences. On September 14, CEO Moshe Mizrahy and CFO Yair Malca will present at the Baird Global Healthcare Conference at 4:20 PM ET. Additionally, they will participate in the Citi Small-Mid Cap Growth Conference on September 17, with opportunities for one-on-one meetings. Access to the conference webcasts can be found here.

InMode Ltd. (Nasdaq: INMD) has launched the EvolveX platform featuring Transform technology, designed for hands-free, non-invasive body transformation with zero downtime. The platform meets rising post-lockdown demand for non-surgical treatments, offering a unique all-in-one solution that remodels skin, treats fat, and sculpts muscles. EvolveX’s innovative features allow physicians to customize treatments addressing specific patient needs, promising consistent results. CEO Moshe Mizrahy emphasized the growing demand for such solutions, backed by InMode's strong R&D pipeline.

InMode Ltd. (Nasdaq: INMD) has launched the EmpowerRF Women's Wellness platform, designed to deliver advanced feminine wellness therapies. This multi-functional solution utilizes various complementary technologies to address a range of conditions such as pain relief, blood circulation, and urinary incontinence. CEO Moshe Mizrahy emphasized the company's commitment to addressing unmet needs in women's wellness, while North American President Shakil Lakhani highlighted InMode's ongoing investment in this market despite competitors withdrawing. The platform aims to improve women's quality of life through minimally invasive procedures.

InMode Ltd. (Nasdaq: INMD), a leader in medical technologies, announced its participation in key upcoming conferences. On August 12, Yair Malca, CFO, will engage in a virtual fireside chat at Canaccord Genuity's Growth Virtual Conference, while Moshe Mizrahy, CEO, joins him for a similar event at UBS Genomics 2.0 in Laguna Beach. Additionally, both executives will be available for one-on-one meetings at the Needham Virtual Med Tech Conference on August 16. For more details, visit InMode's events page.

InMode Ltd. (Nasdaq: INMD) reported a remarkable 184% increase in second-quarter 2021 revenues, reaching $87.3 million, driven primarily by its proprietary surgical technologies. GAAP net income surged to $40.9 million, up from $8.6 million in Q2 2020, with diluted EPS rising to $0.95. The company boasts a strong cash position of $332.9 million. Management's outlook for 2021 anticipates revenues between $305 million and $315 million, with non-GAAP EPS projected between $3.10 and $3.25. InMode is also launching a new platform, Empower, focused on women's health.

InMode Ltd. (Nasdaq: INMD) has announced expectations for its second-quarter 2021 financial results, to be released on July 28, 2021. Preliminary estimates indicate record revenue between $86.5 million and $87.0 million, and Non-GAAP earnings per diluted share in the range of $1.00 to $1.01. The company has also increased its full-year 2021 revenue guidance to between $305 million and $315 million, with a projected non-GAAP gross margin of 84% to 86%.

InMode Ltd. (Nasdaq: INMD), a leader in medical technology, announced that its CFO, Yair Malca, will present at the Jefferies Virtual Healthcare Conference on June 4 at 10:30 a.m. ET. Malca will also be available for one-on-one virtual meetings during the event. A live webcast of the presentation can be accessed here and will be archived for 30 days. InMode specializes in innovative RF technology for various medical fields, including plastic surgery and dermatology.